Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-01Clinical Trial Update: Tazemetostat Plus CHOP in 1L T-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating tazemetostat in combination with CHOP for first-line T-cell lymphomas has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-02-21Clinical Trial Update: CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) [Phase 2, Phase 3]
Clinical trial CELTIC-1 evaluating cerdulatinib in relapsed/refractory peripheral T-cell lymphoma has been withdrawn from the study.
-
CLINICAL_TRIALS withdrawal · 2016-12-01Clinical Trial Update: Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL [Phase 1]
This update reports the withdrawal of a Phase 1 study evaluating volasertib plus romidepsin for relapsed/refractory peripheral T-cell lympho…
-
CLINICAL_TRIALS withdrawal · 2013-11-18Clinical Trial Update: A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma [Phase 3]
A Phase 3 trial evaluating E7777 in combination with CHOP for first-line treatment of peripheral T-cell lymphoma has been withdrawn.